EDB Fibronectin Specific Peptide for Prostate Cancer Targeting

Area of Science:

• Biochemistry
• Oncology
• Molecular Imaging

Background:

• Extradomain-B fibronectin (EDB-FN) is an oncofetal protein involved in cancer progression, including tumorigenesis and epithelial-to-mesenchymal transition (EMT).
• Targeting specific cancer biomarkers like EDB-FN is crucial for developing effective diagnostic and therapeutic strategies.

Purpose of the Study:

• To develop a small peptide specific to EDB-FN for molecular imaging and targeted therapy of prostate cancer.
• To evaluate the efficacy of the peptide in vitro and in vivo models of prostate cancer.

Main Methods:

• Peptide phage display was used to identify a cyclic nonapeptide (ZD2) specific to EDB-FN.
• A ZD2-Cy5 fluorescent conjugate was synthesized for molecular imaging.
• In vitro studies involved TGF-β-induced PC3 cancer cells to assess EDB-FN expression and peptide binding.
• In vivo studies utilized PC3-GFP tumor xenografts in nude mice and human prostate tumor specimens.

Main Results:

• The ZD2 peptide specifically bound to EDB-FN upregulated in TGF-β-induced PC3 cancer cells.
• The ZD2-Cy5 probe effectively delineated PC3-GFP prostate tumors in vivo.
• ZD2-Cy5 showed differential binding to human prostate tumors based on Gleason score, with higher affinity for GS9 compared to GS7.
• No binding was observed in benign prostatic hyperplasia (BPH) tissues.

Conclusions:

• The ZD2 peptide is a highly specific and promising agent for molecular imaging of prostate cancer.
• The ZD2 peptide holds potential for targeted therapy applications in prostate cancer.
• EDB-FN serves as a viable biomarker for prostate cancer detection and characterization.